How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
56
BSX Quote, Financials, Valuation and Earnings
Last price:
$92.80
Seasonality move
:
4.33%
Day range:
$92.94 - $94.46
52-week range:
$85.98 - $109.50
Dividend yield:
0%
P/E ratio:
50.17x
P/S ratio:
7.24x
P/B ratio:
5.94x
Volume:
8.5M
Avg. volume:
10.6M
1-year change:
-8.34%
Market cap:
$139B
Revenue:
$16.7B
EPS (TTM):
$1.87
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.57% | 76.14% | $124.41 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 55.36% | $136.32 |
|
GMED
Globus Medical, Inc.
|
$800.3M | $1.15 | 22.74% | 68.89% | $106.73 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.8B | $2.27 | 16.35% | 10.81% | $611.82 |
|
SOLV
Solventum Corp.
|
$2B | $1.50 | -5.86% | 87.42% | $89.25 |
|
WST
West Pharmaceutical Services, Inc.
|
$795.7M | $1.83 | 9.22% | 34.18% | $345.71 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
$93.79 | $124.41 | $139B | 50.17x | $0.00 | 0% | 7.24x |
|
ABT
Abbott Laboratories
|
$106.05 | $136.32 | $184.4B | 28.64x | $0.63 | 2.26% | 4.18x |
|
GMED
Globus Medical, Inc.
|
$91.83 | $106.73 | $12.3B | 29.68x | $0.00 | 0% | 4.57x |
|
ISRG
Intuitive Surgical, Inc.
|
$522.04 | $611.82 | $185.1B | 66.24x | $0.00 | 0% | 18.81x |
|
SOLV
Solventum Corp.
|
$76.60 | $89.25 | $13.3B | 8.82x | $0.00 | 0% | 1.59x |
|
WST
West Pharmaceutical Services, Inc.
|
$240.53 | $345.71 | $17.3B | 35.63x | $0.22 | 0.35% | 5.81x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
33.99% | 0.384 | 8.31% | 0.81x |
|
ABT
Abbott Laboratories
|
20.25% | 0.321 | -- | 1.12x |
|
GMED
Globus Medical, Inc.
|
2.66% | -0.267 | 1.56% | 2.23x |
|
ISRG
Intuitive Surgical, Inc.
|
-- | 1.051 | -- | 3.42x |
|
SOLV
Solventum Corp.
|
50.75% | 0.850 | 40.57% | 0.94x |
|
WST
West Pharmaceutical Services, Inc.
|
9.03% | 1.594 | 1.61% | 2.02x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
ABT
Abbott Laboratories
|
$6.5B | $2.4B | 10.2% | 29.06% | 20.59% | $2.3B |
|
GMED
Globus Medical, Inc.
|
$486.7M | $134.7M | 9.44% | 10.08% | 17.51% | $209.2M |
|
ISRG
Intuitive Surgical, Inc.
|
$1.9B | $864.3M | 16.57% | 16.59% | 30.16% | $735.6M |
|
SOLV
Solventum Corp.
|
$1.1B | $171M | 13.6% | 42.2% | 8.16% | -$21M |
|
WST
West Pharmaceutical Services, Inc.
|
$293.5M | $173.7M | 15.73% | 17.44% | 21.6% | $133.9M |
Boston Scientific Corp. vs. Competitors
-
Which has Higher Returns BSX or ABT?
Abbott Laboratories has a net margin of 14.91% compared to Boston Scientific Corp.'s net margin of 15.5%. Boston Scientific Corp.'s return on equity of 12.46% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.65.31% $0.50 $35.7B ABTAbbott Laboratories57.09% $1.02 $64.2B -
What do Analysts Say About BSX or ABT?
Boston Scientific Corp. has a consensus price target of $124.41, signalling upside risk potential of 32.64%. On the other hand Abbott Laboratories has an analysts' consensus of $136.32 which suggests that it could grow by 28.55%. Given that Boston Scientific Corp. has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific Corp. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.26 1 0 ABTAbbott Laboratories14 8 0 -
Is BSX or ABT More Risky?
Boston Scientific Corp. has a beta of 0.670, which suggesting that the stock is 33.029% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.854%.
-
Which is a Better Dividend Stock BSX or ABT?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.26% to investors and pays a quarterly dividend of $0.63 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.34% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or ABT?
Boston Scientific Corp. quarterly revenues are $5.1B, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Boston Scientific Corp.'s net income of $755M is lower than Abbott Laboratories's net income of $1.8B. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 50.17x while Abbott Laboratories's PE ratio is 28.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 7.24x versus 4.18x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.7.24x 50.17x $5.1B $755M ABTAbbott Laboratories4.18x 28.64x $11.5B $1.8B
-
Which has Higher Returns BSX or GMED?
Globus Medical, Inc. has a net margin of 14.91% compared to Boston Scientific Corp.'s net margin of 15.47%. Boston Scientific Corp.'s return on equity of 12.46% beat Globus Medical, Inc.'s return on equity of 10.08%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.65.31% $0.50 $35.7B GMEDGlobus Medical, Inc.63.28% $0.88 $4.5B -
What do Analysts Say About BSX or GMED?
Boston Scientific Corp. has a consensus price target of $124.41, signalling upside risk potential of 32.64%. On the other hand Globus Medical, Inc. has an analysts' consensus of $106.73 which suggests that it could grow by 16.22%. Given that Boston Scientific Corp. has higher upside potential than Globus Medical, Inc., analysts believe Boston Scientific Corp. is more attractive than Globus Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.26 1 0 GMEDGlobus Medical, Inc.6 5 0 -
Is BSX or GMED More Risky?
Boston Scientific Corp. has a beta of 0.670, which suggesting that the stock is 33.029% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.426%.
-
Which is a Better Dividend Stock BSX or GMED?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSX or GMED?
Boston Scientific Corp. quarterly revenues are $5.1B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Boston Scientific Corp.'s net income of $755M is higher than Globus Medical, Inc.'s net income of $119M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 50.17x while Globus Medical, Inc.'s PE ratio is 29.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 7.24x versus 4.57x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.7.24x 50.17x $5.1B $755M GMEDGlobus Medical, Inc.4.57x 29.68x $769M $119M
-
Which has Higher Returns BSX or ISRG?
Intuitive Surgical, Inc. has a net margin of 14.91% compared to Boston Scientific Corp.'s net margin of 27.89%. Boston Scientific Corp.'s return on equity of 12.46% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.65.31% $0.50 $35.7B ISRGIntuitive Surgical, Inc.66.56% $2.21 $17.9B -
What do Analysts Say About BSX or ISRG?
Boston Scientific Corp. has a consensus price target of $124.41, signalling upside risk potential of 32.64%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 17.2%. Given that Boston Scientific Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Boston Scientific Corp. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.26 1 0 ISRGIntuitive Surgical, Inc.16 10 1 -
Is BSX or ISRG More Risky?
Boston Scientific Corp. has a beta of 0.670, which suggesting that the stock is 33.029% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.
-
Which is a Better Dividend Stock BSX or ISRG?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSX or ISRG?
Boston Scientific Corp. quarterly revenues are $5.1B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Boston Scientific Corp.'s net income of $755M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 50.17x while Intuitive Surgical, Inc.'s PE ratio is 66.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 7.24x versus 18.81x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.7.24x 50.17x $5.1B $755M ISRGIntuitive Surgical, Inc.18.81x 66.24x $2.9B $799.5M
-
Which has Higher Returns BSX or SOLV?
Solventum Corp. has a net margin of 14.91% compared to Boston Scientific Corp.'s net margin of 60.4%. Boston Scientific Corp.'s return on equity of 12.46% beat Solventum Corp.'s return on equity of 42.2%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.65.31% $0.50 $35.7B SOLVSolventum Corp.53.91% $7.22 $10.1B -
What do Analysts Say About BSX or SOLV?
Boston Scientific Corp. has a consensus price target of $124.41, signalling upside risk potential of 32.64%. On the other hand Solventum Corp. has an analysts' consensus of $89.25 which suggests that it could grow by 16.51%. Given that Boston Scientific Corp. has higher upside potential than Solventum Corp., analysts believe Boston Scientific Corp. is more attractive than Solventum Corp..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.26 1 0 SOLVSolventum Corp.5 5 1 -
Is BSX or SOLV More Risky?
Boston Scientific Corp. has a beta of 0.670, which suggesting that the stock is 33.029% less volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BSX or SOLV?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSX or SOLV?
Boston Scientific Corp. quarterly revenues are $5.1B, which are larger than Solventum Corp. quarterly revenues of $2.1B. Boston Scientific Corp.'s net income of $755M is lower than Solventum Corp.'s net income of $1.3B. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 50.17x while Solventum Corp.'s PE ratio is 8.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 7.24x versus 1.59x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.7.24x 50.17x $5.1B $755M SOLVSolventum Corp.1.59x 8.82x $2.1B $1.3B
-
Which has Higher Returns BSX or WST?
West Pharmaceutical Services, Inc. has a net margin of 14.91% compared to Boston Scientific Corp.'s net margin of 17.41%. Boston Scientific Corp.'s return on equity of 12.46% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.65.31% $0.50 $35.7B WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B -
What do Analysts Say About BSX or WST?
Boston Scientific Corp. has a consensus price target of $124.41, signalling upside risk potential of 32.64%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 43.73%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Boston Scientific Corp., analysts believe West Pharmaceutical Services, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.26 1 0 WSTWest Pharmaceutical Services, Inc.11 3 0 -
Is BSX or WST More Risky?
Boston Scientific Corp. has a beta of 0.670, which suggesting that the stock is 33.029% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.728%.
-
Which is a Better Dividend Stock BSX or WST?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.35% to investors and pays a quarterly dividend of $0.22 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or WST?
Boston Scientific Corp. quarterly revenues are $5.1B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Boston Scientific Corp.'s net income of $755M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 50.17x while West Pharmaceutical Services, Inc.'s PE ratio is 35.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 7.24x versus 5.81x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.7.24x 50.17x $5.1B $755M WSTWest Pharmaceutical Services, Inc.5.81x 35.63x $804.3M $140M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
58
AAOI alert for Jan 29
Applied Optoelectronics, Inc. [AAOI] is down 14.77% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.22% over the past day.
Buy
93
ATEYY alert for Jan 29
Advantest Corp. [ATEYY] is down 8.78% over the past day.
